Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
918.52
-2.97 (-0.32%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eli Lilly
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
98
99
Next >
Eli Lilly's Growth Prospects Just Got a Huge Upgrade
June 20, 2024
The company's promising Alzheimer's drug could soon obtain approval from regulators.
Via
The Motley Fool
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
June 20, 2024
Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
June 19, 2024
Via
Benzinga
Eli Lilly Stock Analysis: Buy, Hold, or Sell?
June 19, 2024
Eli Lilly is ramping up manufacturing to meet the soaring demand for its innovative medicines.
Via
The Motley Fool
Eli Lilly Hits All-Time High, Named To Big Cap 20 List: Check These Lists For Best Stocks To Buy
June 18, 2024
Eli Lilly stock has been on an astounding run. In 2009 its stock sold for 27.21 a share. It closed Tuesday at 891.46, up 3,149% from 2009.
Via
Investor's Business Daily
(LLY) - Analyzing Eli Lilly and Co's Short Interest
June 18, 2024
Via
Benzinga
Here's How Much $1000 Invested In Eli Lilly and Co 10 Years Ago Would Be Worth Today
June 18, 2024
Via
Benzinga
Spotlight on Eli Lilly and Co: Analyzing the Surge in Options Activity
June 17, 2024
Via
Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
June 18, 2024
This stock may not be a slam dunk, but it's looking very promising.
Via
The Motley Fool
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
June 17, 2024
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment.
Via
Investor's Business Daily
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
June 17, 2024
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for...
Via
Benzinga
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
June 16, 2024
Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade.
Via
The Motley Fool
Will Walmart Reach a Trillion-Dollar Market Cap by 2030?
June 16, 2024
This seemingly unlikely non-tech name quietly deserves to be on the list of contenders that could achieve the feat in the foreseeable future.
Via
The Motley Fool
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
June 14, 2024
Via
Benzinga
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
June 15, 2024
The company has too many weapons at its disposal.
Via
The Motley Fool
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
June 15, 2024
The drugmaker continues to make headlines for all the right reasons.
Via
The Motley Fool
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
June 15, 2024
Want peace of mind about your investments? Consider these great stocks.
Via
The Motley Fool
Exit Alert: 3 Stocks to Offload Before the Downturn
June 15, 2024
Discover why three top stocks to sell now are facing challenges in technology hardware, pharmaceuticals and automobile manufacturers.
Via
InvestorPlace
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
June 14, 2024
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
Via
Investor's Business Daily
Stock Market Hits Highs; Tame Inflation, Fed Meeting, Apple, Broadcom, Oracle, Tesla: Weekly Review
June 14, 2024
The Dow Jones fell amid weak-to-lackluster market breadth.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
7 A-Rated Biotech Stocks Worth Betting on in June
June 14, 2024
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.
Via
InvestorPlace
3 Stocks to Sell as Ozempic Surges in Popularity
June 14, 2024
GLP-1s are a weight-loss breakthrough, but these three stocks to sell have a lot to lose from their rapid rise in popularity.
Via
InvestorPlace
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
June 14, 2024
Novo Nordisk's competition in the obesity drug market is heating up.
Via
The Motley Fool
Weight Loss Drugs: Are They Really Magic?
June 13, 2024
Talking about weight and weight loss with Johann Hari, an Ozempic user and the author of "Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs."
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
June 13, 2024
Via
Benzinga
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
June 13, 2024
JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals.
Via
Benzinga
3 Stocks to Buy if You Want to Turn Your $1,000 into $10,000 Within 2 Years
June 13, 2024
One of the best ways to spot winning stocks to buy is by spotting hot trends, such as artificial intelligence and obesity.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Stocks to Buy as Ozempic Surges in Popularity
June 13, 2024
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand.
Via
InvestorPlace
Want to Get Richer? 2 Top Stocks to Buy Now and Hold Forever.
June 13, 2024
These proven wealth builders have what it takes to deliver solid gains long-term.
Via
The Motley Fool
Down 57%, Is AbCellera Biologics a Buy on the Dip?
June 13, 2024
Wall Street analysts say this drug developer can more than double your money.
Via
The Motley Fool
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
98
99
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.